Eric Jacobson
Psychiatry · Monterey, CANPI 1497762397
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 460 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,030 and has fallen 91.4% since, to $175 in 2023. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Sunovion Pharmaceuticals Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$429
- Takeda Pharmaceuticals U.S.A., Inc.$383
- Alkermes, Inc.$375
- plus $2K from 21 others
What the payments were for
- Food & beverage$7,45199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $1,729 |
| Sunovion Pharmaceuticals Inc. | 76 | $1,467 |
| Johnson & Johnson | 108 | $1,212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $429 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $383 |
| Alkermes, Inc. | 21 | $375 |
| Otsuka America Pharmaceutical, Inc. | 22 | $344 |
| Avanir Pharmaceuticals, Inc. | 11 | $251 |
| Lundbeck LLC | 20 | $243 |
| Neurocrine Biosciences, Inc. | 7 | $149 |
| Merck | 8 | $135 |
| Teva Pharmaceuticals USA, Inc. | 7 | $130 |
| Eisai Inc. | 6 | $120 |
| Vanda Pharmaceuticals Inc. | 5 | $114 |
| Indivior Inc. | 6 | $94 |
| Shire North American Group Inc | 3 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Boston Scientific | 2 | $39 |
| Corium, LLC | 1 | $27 |
| Alfasigma USA, Inc. | 1 | $26 |
| Bausch Health US, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Neuronetics, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $13 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$7,497 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Monterey
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.